Brokerages expect Protagonist Therapeutics Inc (NASDAQ:PTGX) to post ($0.54) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Protagonist Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.49) and the lowest estimate coming in at ($0.59). Protagonist Therapeutics reported earnings per share of ($0.41) during the same quarter last year, which would suggest a negative year over year growth rate of 31.7%. The business is expected to announce its next quarterly earnings results on Tuesday, August 6th.

On average, analysts expect that Protagonist Therapeutics will report full-year earnings of ($2.36) per share for the current year, with EPS estimates ranging from ($2.61) to ($2.11). For the next fiscal year, analysts forecast that the firm will post earnings of ($2.11) per share, with EPS estimates ranging from ($2.40) to ($1.81). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that follow Protagonist Therapeutics.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Wednesday, May 8th. The company reported ($0.58) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.59) by $0.01. The business had revenue of $1.56 million during the quarter, compared to analysts’ expectations of $2.50 million. Protagonist Therapeutics had a negative net margin of 209.02% and a negative return on equity of 40.78%.

A number of brokerages have recently issued reports on PTGX. ValuEngine raised shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, May 9th. Zacks Investment Research cut shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, February 22nd. BMO Capital Markets began coverage on shares of Protagonist Therapeutics in a research note on Friday, February 22nd. They issued an “outperform” rating and a $17.00 price objective for the company. Stifel Nicolaus raised shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating and increased their price objective for the stock from $11.00 to $17.00 in a research note on Wednesday, May 8th. Finally, BidaskClub cut shares of Protagonist Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 13th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $16.33.

Shares of NASDAQ PTGX traded up $0.10 during midday trading on Friday, reaching $10.80. The stock had a trading volume of 1,842 shares, compared to its average volume of 149,939. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.02 and a quick ratio of 5.02. The stock has a market cap of $244.26 million, a PE ratio of -6.10 and a beta of 1.96. Protagonist Therapeutics has a 12-month low of $5.49 and a 12-month high of $14.36.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. D. E. Shaw & Co. Inc. grew its stake in Protagonist Therapeutics by 75.5% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 19,645 shares of the company’s stock valued at $132,000 after acquiring an additional 8,450 shares in the last quarter. Bank of Montreal Can grew its stake in Protagonist Therapeutics by 1,675.5% during the first quarter. Bank of Montreal Can now owns 11,026 shares of the company’s stock valued at $139,000 after acquiring an additional 10,405 shares in the last quarter. Jefferies Group LLC purchased a new position in Protagonist Therapeutics during the first quarter valued at $177,000. Bank of America Corp DE grew its stake in Protagonist Therapeutics by 94.3% during the fourth quarter. Bank of America Corp DE now owns 26,419 shares of the company’s stock valued at $178,000 after acquiring an additional 12,819 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Protagonist Therapeutics by 17.2% during the fourth quarter. Northern Trust Corp now owns 34,624 shares of the company’s stock valued at $234,000 after acquiring an additional 5,084 shares in the last quarter. 59.43% of the stock is owned by hedge funds and other institutional investors.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.

Recommended Story: What is Cost of Goods Sold (COGS)?

Get a free copy of the Zacks research report on Protagonist Therapeutics (PTGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.